Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Investing Activities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cash from Investing Activities for 4 consecutive years, with -$2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities rose 85.47% year-over-year to -$2.4 million, compared with a TTM value of $13.1 million through Sep 2025, down 13.88%, and an annual FY2024 reading of $8.6 million, down 93.04% over the prior year.
  • Cash from Investing Activities was -$2.4 million for Q3 2025 at Atara Biotherapeutics, up from -$5.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $70.4 million in Q3 2023 and bottomed at -$16.7 million in Q3 2024.
  • Average Cash from Investing Activities over 4 years is $23.0 million, with a median of $14.7 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities surged 345.0% in 2024, then tumbled 170.46% in 2025.
  • Year by year, Cash from Investing Activities stood at $51.2 million in 2022, then plummeted by 80.58% to $9.9 million in 2023, then plummeted by 66.05% to $3.4 million in 2024, then crashed by 171.71% to -$2.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ATRA at -$2.4 million in Q3 2025, -$5.1 million in Q2 2025, and $17.2 million in Q1 2025.